Exo, maker of a point-of-care ultrasound device and platform, announced Tuesday it has acquired Medo, which offers AI tools for ultrasound imaging.
Medo brings two FDA-cleared algorithms to the combined business. Last year the company received a 510(k) for Medo Thyroid, which helps users identify and evaluate thyroid nodules in adults. Medo Hip, which received the FDA green light in 2020, is used...
Exo a company, best-known for its handheld ultrasounds, scored $220 million in Series C funding this morning. The latest found was led by RA Capital Management with participation from BlackRock, Sands Capital, Avidity Partners and Pura Vida Investments
This news comes just about a year after the Silicon Valley startup closed a $40 million Series B+ round. As of today, the company's total funding...
Exo, a Silicon Valley company known for its in-development handheld ultrasound device, announced $40 million in new funding yesterday. GlaxoSmithKline's Investor Action Potential Venture Capital fund was among the Series B+ round's unnamed investors.
Exo said in its announcement that it will be using the funds to wrap up product development for that device, and to bring its data and workflow apps...
This morning AI-enabled handheld ultrasound startup Exo landed $35 million in Series B funding. The new infusion of cash was led by Intel Capital with participation from Applied Ventures, Bold Capital, Creative Ventures, Longevity Vision Fund, Magnetar Capital, Nautilus Venture Partners, OSF Healthcare, Rising Tide Fund, Sony Innovation Fund and Wanxiang Healthcare Investments.
WHAT THEY DO
The...
